A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Categories (click each to see list of all clinical trials associated with that category): GI (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Tenner, Laura
Contact Information:
Anita Rogic
arogic@unmc.edu
Eligibility: https://www.clinicaltrials.gov/study/NCT05673148?term=NCT05673148&rank=1
Summary
2.1 Primary Objective
To evaluate and compare overall survival (OS) (measured from time of randomization) in patients with newly
diagnosed oligometastatic colorectal cancer (oCRC) treated with total ablative therapy (TAT) in addition to standard
of care (SOC) systemic therapy versus SOC systemic therapy.
2.2 Secondary Objectives
2.2.1 To evaluate and compare event-free survival (EFS) (measured from time of randomization) between the two
treatment arms.
2.2.2 To assess the adverse events (AE) profile within each of the two treatment arms.
2.2.3 To evaluate the time to local recurrence (TLR) (measured from completion of TAT) in patients with newly
diagnosed oCRC treated with TAT + SOC systemic therapy.